Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
TypePublic
HQCambridge, US
Founded1978
Size (employees)7,300 (est)-1%
Websitebiogen.com
Biogen was founded in 1978 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

CEO
Susan Alexander

Susan Alexander

EVP
Jeffrey Capello

Jeffrey Capello

EVP
Michael Ehlers

Michael Ehlers

EVP
Ginger Gregory

Ginger Gregory

EVP
Chirfi Guindo

Chirfi Guindo

EVP
Show more

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St
Show all (1)
Report incorrect company information

Biogen Financials and Metrics

Biogen Revenue

Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
USD

Revenue (Q1, 2017)

2.8 b

Net income (Q1, 2017)

747.5 m

EBIT (Q1, 2017)

1 b

Market capitalization (19-Sep-2018)

68.3 b

Closing stock price (19-Sep-2018)

338.9

Cash (31-Mar-2017)

924 m
Biogen's current market capitalization is $68.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.9 b9.7 b10.8 b11.4 b

Revenue growth, %

40%11%6%

General and administrative expense

1.9 b

R&D expense

2 b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.4 b2.5 b2.6 b2.6 b2.8 b2.7 b2.9 b3 b2.8 b

General and administrative expense

576.6 m570.4 m560.4 m491.9 m477.8 m497.3 m492.4 m462.7 m499.1 m

R&D expense

447.3 m417.2 m460.5 m490.7 m519.9 m437.3 m473.1 m529 m423.4 m

Operating expense total

1 b987.6 m1 b982.6 m997.7 m934.6 m965.5 m991.7 m922.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

602.6 m1.2 b1.3 b2.3 b

Accounts Receivable

824.4 m1.3 b1.2 b1.4 b

Inventories

659 m804 m893.4 m1 b

Current Assets

3.2 b4.7 b6.7 b8.7 b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

863.2 m1.2 b1.5 b1.3 b4.1 b1.1 b1.4 b2.1 b924 m

Accounts Receivable

1 b1.1 b1.4 b1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

Inventories

715.9 m753.1 m825.3 m865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Current Assets

3.9 b4.4 b5.3 b5.6 b9.3 b7.2 b7.4 b8.1 b6.9 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9 b2.9 b3.6 b3.7 b

Depreciation and Amortization

688.2 m600.4 m682.7 m

Inventories

(240 m)(190 m)(170 m)(165.6 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m

Inventories

865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Accounts Payable

282.7 m251.2 m271.3 m225.9 m274 m316.4 m
USDY, 2017

Revenue/Employee

379.8 k

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
FY, 2016

Phase I Trials Products

4

Phase II Trials Products

10

Phase III Trials Products

2

Training Provided, no. of people

40 k
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AliveGenJuly 25, 2018$27.50 m
Karyopharm TherapeuticsJanuary 25, 2018$10 m
Report incorrect company information

Biogen Online and Social Media Presence

Embed Graph
Report incorrect company information

Biogen News and Updates

Recombinant DNA Technology 2018 Global Market Key Players – Monsanto Company, Roche, Biogen, Amgen, Novartis, Eli Lilly and Company, GenScript – Analysis and Forecast to 2025

WiseGuyRerports.com Presents “Global Recombinant DNA Technology Market Size, Status and Forecast 2018-2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022: Key Vendors are Biogen, F. Hoffmann-La Roche, Merck, Novartis & Spectrum Pharmaceuticals

DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global B-Cell Non-Hodgkin Lymphoma Drugs Market to grow at a CAGR of 7.52% during the period 2018-2022. Global B-cell...

Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction

CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced today the enrollment of the first patient in the global Phase 3 clinical study CHARM, designed to evaluate BIIB093 (intravenous (IV) glibenclamide) for the prevention and treatment of severe cerebral edema in larg…

Biogen's pricey muscle drug Spinraza too costly for Britain

Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.

There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong

Experts are questioning a major scientific theory of the disease, which could mean two Biogen drugs won’t be successful.

Biogen's stock gets a boost from new $3.5 billion stock repurchase program

Shares of Biogen Inc. rose 0.6% in premarket trade Friday, after the biotechnology company disclosed the authorization of a $3.5 billion share repurchase program. In a filing with the Securities and Exchange Commission, the company said the repurchase program does not have an expiration date. The c…
Show more
Report incorrect company information

Biogen Company Life and Culture

Report incorrect company information